EAU 2018: Incidence and Survival Trends of De-Novo Metastatic Prostate Cancer – A Population-Based Analysis of Two National Cohorts from USA and Denmark

Copenhagen, Denmark (UroToday.com) Dr. Helgstrand presented results regarding the incidence and survival trends of de-novo metastatic prostate cancer using two population-based datasets. Certainly, early detection has increased prostate cancer incidence, and randomized trials have demonstrated that early detection reduces the incidence of de-novo metastatic prostate cancer. Concurrently, life-prolonging treatments have been introduced for advanced prostate cancer, including many in the CRPC space and metastatic hormone sensitive arena. The objective of this study was to analyze on a population-based level whether early detection and improved treatments changed the incidence and 5-year mortality of men with de-novo metastatic prostate cancer.

For this study, the authors identified men diagnosed with prostate cancer from 1980-2011 in the Surveillance, Epidemiology, and End Results (SEER) program and from 1995-2011 in the Danish Prostate Cancer Registry (DaPCaR), and stratified patients according to period of diagnosis. Age-standardized incidence (according to the world standard population) and 5-year mortality rates were calculated for both cohorts using competing-risk analysis treating PCa-specific death and other-cause death as competing events.

There were 29,555 men in the SEER database and 6,874 men in the DaPCaR database with de-novo metastatic prostate cancer who were identified. The incidence of de-novo metastatic prostate cancer decreased from 12.0 to 4.4 per 100,000 men in the SEER cohort, while a moderate increase from 6.7 to 9.9 per 100,000 was observed in the DaPCaR cohort over the time period of the study. Five-year prostate cancer-specific mortality in SEER was stable from 1980 to 1994 and increased slightly in the latest periods studied (54.2% to 61.0%, p<0.0001), while 5-year disease-specific mortality decreased by 16.6% (from 73.4% to 64.0%, p<0.0001) in the DaPCaR cohort. 
Dr. Helgstrand concluded that despite earlier detection, de-novo metastatic prostate cancer remains associated with a high risk of 5-year prostate cancer-specific mortality. They suggest that the reduced 5-year prostate cancer-mortality in DaPCaR is largely explained by lead-time. Early detection decreased the incidence of de-novo metastatic prostate cancer, as observed in the SEER cohort and might be a key explanation for the reduced prostate cancer-specific mortality observed in the U.S. As Dr. Helgstrand cautions, this must, however, be weighed against the unsolved issue of over-detection and overtreatment of indolent prostate cancer.


Presented by: John T. Helgstrand, Copenhagen University Hospital, Copenhagen, Denmark

Co-Authors: Røder M3, Klemann N, Toft B, Lichtensztajn D, Brooks J, Brasso K, Vainer B, Iversen P

Written by: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre, twitter: @zklaassen_md at the 2018 European Association of Urology Meeting EAU18, 16-20 March, 2018 Copenhagen, Denmark
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe